Literature DB >> 9552427

Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations.

G S Rekhi1, N D Eddington, M J Fossler, P Schwartz, L J Lesko, L L Augsburger.   

Abstract

The purpose of this investigation was to examine the impact of formulation and process changes on dissolution and bioavailability/bioequivalency of metoprolol tartrate tablets manufactured using a high-shear granulation process. A half-factorial (2(4-1), Res IV) design was undertaken to study the selected formulation and processing variables during scale-up. Levels and ranges for excipients and processing changes studied represented level 2 or greater changes as indicated by the SUPAC-IR Guidance. Blend and tableting properties were evaluated. Changes in sodium starch glycolate and magnesium stearate levels, and the order of addition microcrystalline cellulose (intra- vs. extragranular) were significant only in affecting percent drug released (Q) in 5, 10, and 15 min. Statistical analysis of data showed no significant curvature. No interaction effects were found to be statistically significant. To examine the impact of formulation and processing variables on in vivo absorption, three batches were selected for a bioavailability study based on their dissolution profiles. Subjects received four metoprolol treatments (Lopressor, slow-, medium-, and fast-dissolving formulations) separated by 1 week according to a randomized crossover design. After an overnight fast, subjects were administered one tablet (100 mg), blood samples were collected over 24 hr and plasma samples were analyzed. The formulations were found to be bioequivalent with respect to the log Cmax and log AUC0-infinity. The results of this study suggest that: (i) bioavailability/bioequivalency studies may not be necessary for metoprolol tartrate and perhaps other class 1 drugs after level 2 type changes and (ii) in vitro dissolution tests may be used to show bioequivalence of metoprolol formulations with processing or formulation changes within the specified level 2 ranges for the equipment examined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9552427     DOI: 10.3109/10837459709022605

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  7 in total

1.  Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds.

Authors:  Marija Tubic-Grozdanis; Michael B Bolger; Peter Langguth
Journal:  AAPS J       Date:  2008-04-02       Impact factor: 4.009

2.  Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation.

Authors:  N D Eddington; P Marroum; R Uppoor; A Hussain; L Augsburger
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

3.  Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities.

Authors:  J E Polli; M J Ginski
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

4.  Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system.

Authors:  M J Ginski; R Taneja; J E Polli
Journal:  AAPS PharmSci       Date:  1999

5.  Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations.

Authors:  N D Eddington; G S Rekhi; L J Lesko; L L Augsburger
Journal:  AAPS PharmSciTech       Date:  2000-06-17       Impact factor: 3.246

6.  Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs.

Authors:  E Galia; E Nicolaides; D Hörter; R Löbenberg; C Reppas; J B Dressman
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

7.  Generalized in vitro-in vivo relationship (IVIVR) model based on artificial neural networks.

Authors:  Aleksander Mendyk; Paweł K Tuszyński; Sebastian Polak; Renata Jachowicz
Journal:  Drug Des Devel Ther       Date:  2013-03-27       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.